SEC Form 4 · accession 0001615774-17-000876
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 28, 2017
Accepted (ET)
Mar 2, 2017 · 8:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2017 | S | 195,734 | $30.50 | D | 3,017,798 | I | By Vivo Ventures Fund VII, L.P. |
| Common StockF2 | Feb 28, 2017 | S | 4,266 | $30.50 | D | 65,771 | I | By Vivo Ventures VII Affiliates Fund, L.P. |
| Common StockF3,F1 | Mar 1, 2017 | S | 97,867 | $30.98 | D | 2,919,931 | I | By Vivo Ventures Fund VII, L.P. |
| Common StockF3,F2 | Mar 1, 2017 | S | 2,133 | $30.98 | D | 63,638 | I | By Vivo Ventures VII Affiliates Fund, L.P. |
| Common StockF4,F1 | Mar 2, 2017 | S | 122,334 | $31.20 | D | 2,797,597 | I | By Vivo Ventures Fund VII, L.P. |
| Common StockF4,F2 | Mar 2, 2017 | S | 2,666 | $31.20 | D | 60,972 | I | By Vivo Ventures VII Affiliates Fund, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F2Vivo Ventures VII, LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures VII Affiliates Fund, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F3The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.20, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.86, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.